Haemonetics CORP: directors' dealings · United States · SEC (Form 4)

About Haemonetics CORP

Haemonetics Corp. (NYSE: HAE) is a U.S.-based medical technology company focused on blood and plasma management, hemostasis, and related hospital solutions. The company is headquartered in Boston, Massachusetts, in the United States, and traces its origins back to 1971, when it was founded as a medical device company built around automated blood component collection and surgical blood salvage technologies. Over time, Haemonetics has evolved from a narrower blood-management specialist into a more diversified medtech platform serving three core reporting segments: Plasma, Blood Center, and Hospital. ([sec.gov](https://www.sec.gov/Archives/edgar/data/313143/000031314325000025/hae-20250329.htm?utm_source=openai)) Its Plasma segment is the historical and strategic core of the business. This division provides end-to-end plasma collection technologies, software, and related services designed to improve donor safety, operational efficiency, and center productivity. Management has highlighted this business as its largest revenue contributor, while also noting that it can be affected by client investment cycles and temporary changes in collection volumes. The Blood Center segment supplies devices and technologies used by blood centers to collect blood components and optimize yields and costs. In fiscal 2025, Haemonetics completed the divestiture of its Whole Blood product line, a move intended to sharpen the portfolio toward higher-margin and higher-growth opportunities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000313143/000031314325000043/hae2025annualreporttoshare.pdf?utm_source=openai)) The Hospital segment has become increasingly important to the investment case. It consists of two franchises: Interventional Technologies and Blood Management Technologies. Interventional Technologies includes vascular closure devices, sensor-guided products, and esophageal protection solutions acquired through the Attune Medical transaction in 2024. Blood Management Technologies includes hemostasis management, cell salvage, and transfusion management products. Haemonetics has emphasized that both franchises hold leading positions in their niches and support hospitals’ efforts to reduce procedural costs while maintaining high standards of care. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000313143/000031314325000043/hae2025annualreporttoshare.pdf?utm_source=openai)) From a competitive standpoint, Haemonetics is a specialized player rather than a broad-based medtech giant, but it holds meaningful positions in select categories of plasma collection and hospital blood-management technologies. Its installed base and recurring consumables profile are important strengths, while its global footprint provides reach across developed and emerging markets. The company reports manufacturing and operating presence in the United States, Mexico, Malaysia, Canada, China, and India, reinforcing its international supply chain and customer coverage. ([sec.gov](https://www.sec.gov/Archives/edgar/data/313143/000031314325000025/hae-20250329.htm?utm_source=openai)) Recent strategic developments have been notable: product launches in both hospital franchises, the integration of Attune Medical, the sale of the Whole Blood line, debt refinancing, a $700 million convertible note issuance, and an ongoing share repurchase program. For investors, Haemonetics remains a NYSE-listed U.S. healthcare company with a clearer focus on higher-value medtech niches, recurring revenue streams, and operational discipline. ([sec.gov](https://www.sec.gov/Archives/edgar/data/313143/000031314325000041/hae-20250605.htm?utm_source=openai))